目的 探討血栓通膠囊治療腦梗死（瘀血阻絡(luò)證）的臨床療效。方法 選擇2011年11月-2012年11月在黑龍江中醫(yī)藥大學(xué)附屬第二醫(yī)院等6家醫(yī)院就診的恢復(fù)期腦梗死（瘀血阻絡(luò)證）患者201例，隨機(jī)分為對照組（51例）和治療組（150例）。對照組口服銀杏葉膠囊，2粒/次，3次/d。治療組口服血栓通膠囊，2粒/次，3次/d。兩組患者均治療4周。觀察兩組的臨床療效，比較兩組的美國國立衛(wèi)生研究所卒中量表（NIHSS）評(píng)分、日常生活能力量表（ADL）評(píng)分和改良Rankin量表情況。結(jié)果 治療后，對照組和治療組的中醫(yī)證候、偏身麻木、頭痛、頭暈治療總有效率分別為74.51%、98.33%，55.26%、74.34%，88.89%、94.51%，69.23%、87.50%，兩組比較差異有統(tǒng)計(jì)學(xué)意義（P<0.05）。治療后，兩組NIHSS評(píng)分均顯著下降，ADL評(píng)分均顯著上升，同組治療前后比較差異有統(tǒng)計(jì)學(xué)意義（P<0.05）；且治療組這些觀察指標(biāo)的改善程度明顯優(yōu)于對照組，兩組比較差異具有統(tǒng)計(jì)學(xué)意義（P<0.05）。治療后，兩組改良Rankin量表的0、1、2級(jí)的比例均顯著上升，3、4、5級(jí)均顯著下降，同組治療前后比較差異有統(tǒng)計(jì)學(xué)意義（P<0.05）。結(jié)論 血栓通膠囊治療腦梗死（瘀血阻絡(luò)證）具有較好的臨床療效，可改善臨床癥狀，提高生活質(zhì)量，且安全性較好，具有一定的臨床推廣應(yīng)用價(jià)值。

Objective To evaluate the clinical efficacy of Xueshuantong Capsules in treatment of cerebral infarction (syndrome of blood stasis obstructing collaterals). Methods Patients (201 cases) with convalescent cerebral infarction in 6 hospitals, such as the Second Affiliated Hospital of Heilongjiang University of Chinese Medicine from November 2011 to November 2012 were randomly divided into the control group (51 cases) and the treatment group (150 cases). Patients in the control group were po administered withYinxingye Capsules, 2 grains/time, three times daily. Patients in the treatment group were po administered with Xueshuantong Capsules, 2 grains/time, three times daily. Patients in two groups were treated for 4 weeks. After treatment, the clinical efficacies were evaluated, and NIHSS scores, ADL scores, and modified Rankin scale in two groups were compared. Results After treatment, symptom efficacies of Traditional Chinese Medicine, hemianesthesia efficacies, headache efficacies, and dizzy efficacies in the control and treatment groups were 74.51% and 98.33%, 55.26% and 74.34%, 88.89% and 94.51%, 69.23% and 87.50%, respectively, and there was difference between two groups (P<0.05). After treatment, the NIHSS scores in two groups were significantly decreased, but the ADL scores in two groups were significantly increased, and the difference was statistically significant in the same group (P<0.05). And the observational indexes in the treatment group were significantly better than those in the control group, with significant difference between two groups (P<0.05). After treatment, the proportion of 0, 1, and 2 grade of modified Rankin scale in two groups were significantly increased, but the proportion of 3, 4, and 5 grade of modified Rankin scale in two groups were significantly decreased, and the difference was statistically significant in the same group (P<0.05). Conclusion Xueshuantong Capsules has clinical curative effect in treatment of cerebral infarction (syndrome of blood stasis obstructing collaterals), can improve clinical symptoms, and raise the quality of life, with good safety, which has a certain clinical application value.